drugset / Trial / NCT00994214
Study to Assess the Efficacy and Safety of Repeated Administration of BIM 23A760 in Patients With Acromegaly
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to assess the efficacy of repeated subcutaneous (under the skin) injections at different doses of BIM 23A760 on growth hormone and insulin-like growth factor-1 levels in patients with acromegaly after 6 months of treatment.
Timeline
- Start
- 2009-10
- Primary completion
- 2011-02
- Completion
- 2011-02
Outcome
Outcome not reported
Stopped: “Preliminary data from this study does not support expected inhibition of GH and IGF-1”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ONZIGOLIDE | Unknown | 1 mg | Subcutaneous |
| Subject | ONZIGOLIDE | Unknown | 2 mg | Subcutaneous |
| Subject | ONZIGOLIDE | Unknown | 4 mg | Subcutaneous |
| Subject | ONZIGOLIDE | Unknown | 6 mg | Subcutaneous |